Global Gastrointestinal Therapeutics Market to Grow at 4.23% During 2025-2033, Spurred by Increasing Incidences of Gastrointestinal Disorders

January 03, 2025 | Healthcare

According to the latest report by IMARC Group, titled "Gastrointestinal Therapeutics Market Report by Type (Branded, Generic), Route of Administration (Oral, Intravenous, and Others), Application (Ulcerative Colitis, Crohn's Disease, GERD, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Region 2025-2033," the global gastrointestinal therapeutics market size reached USD 48.5 Billion in 2024. Gastrointestinal disorders refer to medical conditions that are related to the gastrointestinal tract and the functioning of accessory digestive organs, such as the pancreas, stomach, small and large intestines, gall bladder and rectum. Some of the most common gastrointestinal disorders may include indigestion, constipation, peptic ulcer diseases, and irritable bowel syndrome, which are usually characterized by heartburn, stomachache, bloating, vomiting, and nausea. Gastrointestinal therapeutics is a branch of medicine that aids in the treatment of such ailments by reducing gastric acidity, improving digestion and properly regulating water flow in the gastrointestinal tract. These therapeutics include various over-the-counter (OTC) and prescription drugs, such as laxatives, antacids, antiemetics, antidiarrheal agents, and antiulcer agents.

Global Gastrointestinal Therapeutics Market Trends:

The global market is primarily driven by the rising prevalence of gastrointestinal diseases across the globe. Several ailments, such as constipation, diarrhea and gastroesophageal reflux disease (GERD), are commonly caused due to the shifting lifestyle preferences and the changing dietary patterns of the masses that have led to an increase in the consumption of unhealthy food. This, along with the rising healthcare expenditure, is providing a boost to the uptake of gastrointestinal therapeutics on the global level. Moreover, there has been a considerable rise in the geriatric population that is more prone to develop these gastrointestinal conditions. This, coupled with the easy availability of OTC gastrointestinal drugs through organized online and offline pharmacies, is expected to create a positive outlook for the market. The increasing usage of biosimilars and cellular therapies for the treatment of gastrointestinal disorders that offer personalized and targeted treatment to the patients is also creating a positive outlook for the market. Some of the other factors contributing to the market growth include the rising utilization of regenerative medicines, extensive research and development (R&D) activities, increasing numbers of clinical trials with accurate results to offer innovative therapies to the patients, and the significant developments in the overall healthcare infrastructure. Looking forward, the market value is projected to reach USD 71.8 Billion by 2033, expanding at a CAGR of 4.23% during 2025-2033.

Market Summary:

  • On the basis of the type, the market has been bifurcated into branded and generic.
  • Based on the route of administration, the market has been divided into oral, intravenous, and others.
  • On the basis of the application, the market has been classified into ulcerative colitis, Crohn’s disease, GERD, and others.
  • Based on the distribution channel, the market has been segmented into hospital, retail and online pharmacies.
  • On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.
  • The competitive landscape of the market has been studied in the report with the detailed profiles of the key players. Some of these players include Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., and Takeda Pharmaceuticals.

Report Scope:

Report Features Details
Base Year of the Analysis 2024
Historical Period 2019-2024
Forecast Period 2025-2033
Units Billion USD
Segment Coverage Type, Route of administration, Application, Distribution Channel, Region
Region Covered Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Bausch Health Companies Inc., Bayer Aktiengesellschaft, GlaxoSmithKline Plc, Janssen Biotech Inc. (Johnson & Johnson), Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Takeda Pharmaceuticals.
Customization Scope 10% Free Customization
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N Gould St, Ste R
Sheridan, WY (Wyoming) 82801 USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Gastrointestinal Therapeutics Market to Grow at 4.23% During 2025-2033, Spurred by Increasing Incidences of Gastrointestinal Disorders
Purchase Options New Year Sale
Benefits of Customization
  • Personalize this research
  • Triangulate with your data
  • Get data as per your format and definition
  • Gain a deeper dive into a specific application, geography, customer, or competitor
  • Any level of personalization

Get in Touch With Us

UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-714-6104

Email: sales@imarcgroup.com

Client Testimonials